MU
Publications
7
Views
657
Downloads
496
Supervised works
0
Items per page
1 - 7 of 7
Title Published in Access level OA Policy Year Views Downloads
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trialExperimental hematology & oncology
accessLevelPublic
2025 12 11
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid TumorsCancer research communications
accessLevelPublic
2024 94 109
LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapyESMO Congress 2023
accessLevelPublic
2023 102 38
Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteinsiScience
accessLevelPublic
2023 91 37
Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer modelAACR Annual Meeting 2023
accessLevelPublic
2023 60 76
Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumorsESMO Congress 2022
accessLevelPublic
2022 75 96
Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technologyMolecular therapy. Methods & clinical development
accessLevelPublic
2022 223 129
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack